PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
December 18, 2022International Journal of Gynecology & Obstetrics13 citations

Treatment for mild hypertension in pregnancy with different strategies: A systematic review and meta‐analysis

View Full Paper
ZCZhichao ChenJWJing WangCCCiriaco Carru

Key Result

Antihypertensive treatment for mild pregnancy hypertension significantly reduced the risk of preeclampsia (OR 0.55; 95% CI 0.39-0.78) compared to placebo or no therapy.

Study Design

Type

Meta-Analysis (n=4,211)

Structured PICO

Does antihypertensive treatment prevent preeclampsia and other adverse outcomes in pregnant women with mild hypertension?

P
Population
4,211 pregnant women with mild pregnancy-induced or chronic hypertension across 8 randomized controlled trials.
I
Intervention
Antihypertensive treatment (tight or less-tight control)
C
Comparator
Placebo or no therapy
O
Outcome
Preeclampsiahard clinical

Antihypertensive treatment for mild hypertension in pregnancy significantly improves maternal and pregnancy outcomes without increasing fetal risks.

Main Result

Odds Ratio: 0.55 (95% CI 0.39–0.78)

Abstract

OBJECTIVES: To synthesize the evidence from randomized controlled trials (RCTs) of antihypertensive treatment for mild pregnancy hypertension. METHODS: We searched various databases from inception to June 2022, using keywords including hypertension; pregnancy; therapy; treatment; pregnancy outcomes; maternal outcomes; and perinatal outcomes. Only RCTs of antihypertensive treatment for mild hypertension in pregnancy comparing placebo/no therapy were included. We used Review Manager version 5.3 for statistical analyses. RESULTS: In all, eight studies were eligible, with a total of 4211 participants. Compared with control, the active treatment significantly prevented preeclampsia (OR 0.55; 95%CI, 0.39-0.78), placental abruption (OR 0.39; 95%CI, 0.17-0.91), severe hypertension (OR 0.35; 95%CI, 0.17-0.71), end-organ dysfunction (OR 0.34; 95%CI, 0.19-0.62) and preterm birth (OR 0.69; 95%CI, 0.59-0.82), with no increased risk of small for gestational age (SGA) (OR 1.25; 95%CI, 0.78-2.00), or admission to the NICU (OR 0.83; 95%CI, 0.54-1.28). Subgroup analyses demonstrated that the tight control group did not show an advantage over the less-tight control group in improving pregnancy outcomes. CONCLUSION: In pregnant women with mild pregnancy-induced hypertension or chronic hypertension, antihypertensive treatment still provided precise benefits of improving pregnancy outcomes without increased risk in fetal outcomes.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chen et al. (2022) conducted a meta-analysis in mild pregnancy hypertension (n=4,211). antihypertensive treatment vs. placebo/no therapy was evaluated on preeclampsia (OR 0.55, 95% CI 0.39-0.78). Antihypertensive treatment for mild pregnancy hypertension significantly reduced the risk of preeclampsia (OR 0.55; 95% CI 0.39-0.78) compared to placebo or no therapy.

synapsesocial.com/papers/6a63195a1ec0c1a689b6e5c6https://doi.org/10.1002/ijgo.14634
Ask AI
Helpful
Bookmark
Share
View Full Paper